Deregulation of new genomic techniques before decision
After the EU Parliament's Agriculture (AGRI) Committee called for a patent ban on NGT-1 breeds on 8 January, the ENVI Committee will give its input to the EU Commissions draft […]
Amsilk partners with 21st.BIO
AMSilk GmbH and Danish 21st.BIO A/S announce partnership to accelerate the production of advanced materials made from spider silk-based proteins.
Onera Health raises US$32m in Series C round
Sleep diagnostics specialist Onera Health NV has closed a €30m (US$32m) Series C financing round co-led by EQT Life Sciences and Gimv.
Spexis sells antibiotics programme to Basilea
Macrocycle library secialist Spexis AG is set to sell a preclinical antibiotics programme afor CHF2m to Basilea Pharmaceutica Ltd.
Finnish Enifer Oy secures €12m grant to scale up
Microbial production specialist Enifer has secured a €12m grant from Business Finland to build a mycoprotein ingredient factory with a capacity of 300,000 tonnes annually.
Mogu Srl raises €11m to scale mycelium technology
Italian mycelium specialist Mogu Srl has closed a €11m Series A financing co-led by CDP Venture Capital and the European Circular Bioeconomy Fund (ECBF VC)
Novo Nordisk Foundation in US$25m partnership with CARB-X
Novo Nordisk Foundation has partnered with CARB-X investing US$25m to help SMEs to fight drug-resistant infections.<br /><br />
Novartis AG to buy immunology specialist Calypso Biotech BV
<a title="http://www.b3cnewswire.com/PRT/link.php?click=1630-2-24167-8B20BDBA70E6BDF1B5F7FEECBC3EA611CB7D4F450000" target="_blank" rel="nofollow noopener" href="http://www.b3cnewswire.com/PRT/link.php?click=1630-2-24167-8B20BDBA70E6BDF1B5F7FEECBC3EA611CB7D4F450000">Calypso Biotech BV</a> has entered into an agreement to be acquired by Novartis AG, which will pay. Calypso’s US$250m upfront upon closing plus of up […]
GLP1 agonists: FDA investigates suicide risk
Following in the footsteps of the European Medicines Agency (EMA), the US FDA is now also investigating the side effects of obesity blockbusters.<br /><br /><br />
Boehringer Ingelheim enters €410m licence deal with Kyowa Kirin Co., Ltd.
Boehringer Intelheim is expanding its antfibrotics pipeline licencing a first-in-class treatment for fibro-inflammatory diseases from Kyowa Kirin Co. Ltd. <br /><br />